JP2019504321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504321A5 JP2019504321A5 JP2018538107A JP2018538107A JP2019504321A5 JP 2019504321 A5 JP2019504321 A5 JP 2019504321A5 JP 2018538107 A JP2018538107 A JP 2018538107A JP 2018538107 A JP2018538107 A JP 2018538107A JP 2019504321 A5 JP2019504321 A5 JP 2019504321A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- target
- tdb
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021155968A JP2022023062A (ja) | 2016-01-25 | 2021-09-24 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
| JP2023097744A JP2023138948A (ja) | 2016-01-25 | 2023-06-14 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662286862P | 2016-01-25 | 2016-01-25 | |
| US62/286,862 | 2016-01-25 | ||
| PCT/US2017/014974 WO2017132279A1 (en) | 2016-01-25 | 2017-01-25 | Methods for assaying t-cell dependent bispecific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155968A Division JP2022023062A (ja) | 2016-01-25 | 2021-09-24 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504321A JP2019504321A (ja) | 2019-02-14 |
| JP2019504321A5 true JP2019504321A5 (enExample) | 2020-03-05 |
| JP7438662B2 JP7438662B2 (ja) | 2024-02-27 |
Family
ID=57966203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538107A Active JP7438662B2 (ja) | 2016-01-25 | 2017-01-25 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
| JP2021155968A Withdrawn JP2022023062A (ja) | 2016-01-25 | 2021-09-24 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
| JP2023097744A Pending JP2023138948A (ja) | 2016-01-25 | 2023-06-14 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155968A Withdrawn JP2022023062A (ja) | 2016-01-25 | 2021-09-24 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
| JP2023097744A Pending JP2023138948A (ja) | 2016-01-25 | 2023-06-14 | Ｔ細胞依存性二重特異的抗体をアッセイするための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11513127B2 (enExample) |
| EP (1) | EP3408671B1 (enExample) |
| JP (3) | JP7438662B2 (enExample) |
| CN (2) | CN109073635A (enExample) |
| WO (1) | WO2017132279A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| HRP20201779T1 (hr) | 2015-05-28 | 2021-01-22 | Genentech, Inc. | Stanični test za otkrivanje anti-cd3 homodimera |
| DK3310814T5 (da) | 2015-06-16 | 2024-10-07 | Hoffmann La Roche | Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| BR112020013910A2 (pt) * | 2018-01-08 | 2020-12-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | composições e métodos para alvejamento de cânceres que expressam cd99 |
| CN111699200B (zh) | 2018-01-15 | 2023-05-26 | 南京传奇生物科技有限公司 | 针对pd-1的单域抗体和其变体 |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| CN108918892B (zh) * | 2018-08-01 | 2021-04-27 | 百奥泰生物制药股份有限公司 | 一种测定抗vegf抗体活性的方法及其应用 |
| CN110872356B (zh) * | 2018-09-03 | 2023-06-13 | 广西慧宝源健康产业有限公司 | 双特异性抗体及其使用方法 |
| EP3850013A4 (en) | 2018-09-10 | 2022-10-05 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF |
| TW202028244A (zh) * | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | 用於確定突觸形成之方法及系統 |
| CN109402168A (zh) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用 |
| CN112798786B (zh) * | 2019-11-14 | 2022-04-29 | 深圳先进技术研究院 | 一种基于荧光素酶互补的生物传感器及其制备方法和应用 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| AU2021239929A1 (en) * | 2020-03-16 | 2022-10-13 | Crispr Therapeutics Ag | T-cell bispecific binding proteins |
| WO2022067005A1 (en) * | 2020-09-27 | 2022-03-31 | Genentech, Inc. | High throughput multiparametric immune cell engager screening assay |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| CN112458149B (zh) * | 2020-12-03 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种以cd3为靶点的抗体药物对t细胞激活程度的检测方法 |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| WO2023250485A1 (en) | 2022-06-23 | 2023-12-28 | LAVA Therapeutics N.V. | Assay for t cell dependent multispecific compounds |
| EP4573125A1 (en) * | 2022-08-18 | 2025-06-25 | Immunocore Limited | Multi-domain binding molecules |
| CN120077068A (zh) * | 2022-08-18 | 2025-05-30 | 英美偌科有限公司 | 多结构域结合分子 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| AU2814897A (en) * | 1996-04-25 | 1997-11-12 | T Cell Sciences, Inc. | Method of isolating regulators of t cell activation |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP1565200A4 (en) | 2002-11-27 | 2009-06-24 | Agensys Inc | NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2010129304A2 (en) * | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| WO2013026839A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP2769989A1 (en) * | 2013-02-21 | 2014-08-27 | Universitätsklinikum Freiburg | Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor |
| IL311390A (en) | 2013-03-15 | 2024-05-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| ES2905615T3 (es) * | 2014-11-20 | 2022-04-11 | Promega Corp | Sistemas y métodos para evaluar moduladores de puntos de control inmunitario |
| HRP20201779T1 (hr) | 2015-05-28 | 2021-01-22 | Genentech, Inc. | Stanični test za otkrivanje anti-cd3 homodimera |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| WO2018108759A1 (en) * | 2016-12-13 | 2018-06-21 | F. Hoffmann-La Roche Ag | Method to determine the presence of a target antigen in a tumor sample |
-
2017
- 2017-01-25 CN CN201780015452.9A patent/CN109073635A/zh active Pending
- 2017-01-25 US US16/072,486 patent/US11513127B2/en active Active
- 2017-01-25 EP EP17703606.8A patent/EP3408671B1/en active Active
- 2017-01-25 WO PCT/US2017/014974 patent/WO2017132279A1/en not_active Ceased
- 2017-01-25 JP JP2018538107A patent/JP7438662B2/ja active Active
- 2017-01-25 CN CN202511302206.4A patent/CN121364307A/zh active Pending
-
2021
- 2021-09-24 JP JP2021155968A patent/JP2022023062A/ja not_active Withdrawn
-
2022
- 2022-10-14 US US18/046,865 patent/US20230280355A1/en active Pending
-
2023
- 2023-06-14 JP JP2023097744A patent/JP2023138948A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504321A5 (enExample) | ||
| Karsten et al. | A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis | |
| Kim et al. | The first-week proliferative response of peripheral blood PD-1+ CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors | |
| Labernadie et al. | A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion | |
| JP2018521635A5 (enExample) | ||
| Fichtner et al. | Covalent and density-controlled surface immobilization of E-cadherin for adhesion force spectroscopy | |
| HRP20201779T1 (hr) | Stanični test za otkrivanje anti-cd3 homodimera | |
| WO2010002911A3 (en) | Methods and materials for monitoring myeloma using quantitative mass spetrometry | |
| JP2016501843A5 (enExample) | ||
| EP3404410A3 (en) | Biosensor system for the rapid detection of analytes | |
| EP2564202A1 (en) | Methods for detecting antibodies | |
| JP2012073260A5 (enExample) | ||
| JP2017535273A (ja) | 免疫チェックポイントの調節因子を評価するためのシステム及び方法 | |
| Yu et al. | Characterization of CD45−/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies | |
| Paolini et al. | Differential predictive value of resident memory CD8+ T cell subpopulations in patients with non-small-cell lung cancer treated by immunotherapy | |
| Ma et al. | Protracted yet coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ T cells during convalescence | |
| Park et al. | Flow cytometric immunoassay using E. coli with autodisplayed Z-domains | |
| JP2023182602A (ja) | シナプス形成を決定するための方法およびシステム | |
| Moreno et al. | Analysis of chemokine receptor CCR7 expression on porcine blood T lymphocytes using a CCL19-Fc fusion protein | |
| González-González et al. | Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region | |
| Thoren et al. | Quantitation of infliximab and detection of antidrug antibodies in serum by use of surface plasmon resonance | |
| WO2024255853A1 (en) | Cell-based assays using immobilized recombinant proteins to measure immune regulation of therapeutic biologics | |
| MX2017005156A (es) | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. | |
| US20230408492A1 (en) | Flow based assays for therapeutics | |
| US20160084828A1 (en) | Automatable method for the identification, quantification and discrimination of specific signals in relation to non-specific signals in detection methods by means of a detector |